Abstract
Influenza significantly impacts public health, particularly among the elderly and those with underlying health conditions, but it also imposes substantial economic and operational burdens on the working-age population. This study introduces a novel machine learning-based Susceptible-Infected-Recovered (SIR) model solved as an agent-based model (ABM), designed to dynamically simulate influenza spread and assess the cost-benefit of vaccination programs specifically for frontline workers. Unlike traditional models, our approach accounts for the diverse contact rates and risk profiles across different job types, offering a more granular and accurate prediction of influenza’s impact on workforce productivity. We utilised historical influenza data from the CDC and WHO/FluMart to model the effects of varying vaccination coverage levels on infections, sick days, and associated costs within a typical workplace. The results demonstrate that higher vaccination coverage significantly reduces both the total number of infections and the peak sickness levels, leading to substantial cost savings. Additionally, higher vaccination coverage was associated with a significantly lower peak in sickness, mitigating periods of high absenteeism and operational disruptions. The model highlights the economic advantages of vaccination programs, particularly for sectors with higher salaries and absenteeism rates. It also underscores the importance of targeting frontline workers, who have higher contact rates and contribute more significantly to influenza transmission. This model’s ability to capture the dynamic nature of influenza transmission and its differential effects on various work types represents a significant advancement over previous static models. It provides a robust tool for organisations to optimise vaccination strategies, ensuring business continuity and enhancing productivity during influenza seasons.
Competing Interest Statement
All authors are current or previous employees of Airfinity Ltd.
Funding Statement
This study was funded by Airfinity Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data from the US CDC and The WHO that were originally located at: https://www.cdc.gov/flu/fluvaxview/2023season.html https://www.cdc.gov/flu-burden/php/about/index.html?CDC_AAref_Val=https://www.cdc.gov/flu/about/burden/past-seasons.html https://www.who.int/tools/RespiMart
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors